These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Peng KW; Donovan KA; Schneider U; Cattaneo R; Lust JA; Russell SJ Blood; 2003 Apr; 101(7):2557-62. PubMed ID: 12433686 [TBL] [Abstract][Full Text] [Related]
43. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients. Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970 [TBL] [Abstract][Full Text] [Related]
44. Measles virus for cancer therapy. Russell SJ; Peng KW Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112 [TBL] [Abstract][Full Text] [Related]
45. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500 [TBL] [Abstract][Full Text] [Related]
46. High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Suksanpaisan L; Russell SJ; Peng KW Cancer Gene Ther; 2014 Jun; 21(6):256-60. PubMed ID: 24874841 [TBL] [Abstract][Full Text] [Related]
47. The contenders. Vaccines and viruses take aim at cancer cells. Clancy F Minn Med; 2005 Apr; 88(4):24-8. PubMed ID: 15940888 [No Abstract] [Full Text] [Related]
48. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634 [TBL] [Abstract][Full Text] [Related]
49. Immunosuppression caused by measles virus: role of viral proteins. Kerdiles YM; Sellin CI; Druelle J; Horvat B Rev Med Virol; 2006; 16(1):49-63. PubMed ID: 16237742 [TBL] [Abstract][Full Text] [Related]
50. [Advances in measles virus for cancer therapy]. Zhou D; Zhao ZY Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 44(4):458-64. PubMed ID: 26555426 [TBL] [Abstract][Full Text] [Related]
51. Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity. Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Puri RK; Russell SJ; Galanis E Mol Ther; 2008 Sep; 16(9):1556-1564. PubMed ID: 28189011 [TBL] [Abstract][Full Text] [Related]
52. MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Geekiyanage H; Galanis E Mol Oncol; 2016 Nov; 10(9):1387-1403. PubMed ID: 27507538 [TBL] [Abstract][Full Text] [Related]
53. Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective. Kleinlützum D; Hanauer JDS; Muik A; Hanschmann KM; Kays SK; Ayala-Breton C; Peng KW; Mühlebach MD; Abel T; Buchholz CJ Front Oncol; 2017; 7():127. PubMed ID: 28695108 [TBL] [Abstract][Full Text] [Related]
54. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. Mader EK; Butler G; Dowdy SC; Mariani A; Knutson KL; Federspiel MJ; Russell SJ; Galanis E; Dietz AB; Peng KW J Transl Med; 2013 Jan; 11():20. PubMed ID: 23347343 [TBL] [Abstract][Full Text] [Related]